Novo Nordisk CEO Mike Doustdar says food companies share responsibility as GLP-1 use reshapes demand, including in Mexico, where 36.9% of adults have obesity.
Recap by typeshit. Full story at Mexico Business News.
11:54
Ryan Sims of Optimal Health Project gives a follow-up on how things have gone in the months since his 35-pound loss on the experimental drug.
The Tico Times reports Costa Rica's public system is considering offering GLP-1 weight loss drugs to patients. Tap through for where the discussion stands.
Fiscal.ai posted a chart comparing Lilly and Novo Nordisk and says Lilly is pulling ahead in the obesity drug market. Only the chart is shared, with no other detail.
A short clip of Rosie O'Donnell discussing the tirzepatide drug Mounjaro. Few details are given beyond the title.
The ASCO Post reports that patients with inflammatory bowel disease who used a GLP-1 receptor agonist had about half the odds of colorectal cancer.
Wellness influencers tout peptides for muscle repair, aging and immunity. Many of the synthetic ones being promoted have no FDA approval.
Loading…